EU PFAS Restriction for Medical Devices: REACH Timelines and Derogations

How the EU REACH PFAS restriction affects medical device components, key transition timelines (5- and 12-year derogations), concentration limits, and substitution roadmaps.

EU PFAS Restrictions: The Upcoming Regulatory Landscape

For medical device and in vitro diagnostic (IVD) manufacturers, the European Union's proposed universal restriction on per- and polyfluoroalkyl substances (PFAS) under the REACH Regulation represents one of the most sweeping and complex material-compliance challenges in decades. Fluoropolymers and other fluorinated substances are pervasive across the medtech supply chain, prized for their unique properties including biocompatibility, chemical inertness, low friction, thermal stability, and dielectric strength.

The restriction proposal, originally submitted by the dossiers of five national authorities (Germany, the Netherlands, Denmark, Sweden, and Norway), aims to ban the manufacture, placing on the market, and use of more than 10,000 PFAS compounds. However, recognizing the critical role these materials play in healthcare, regulators are establishing a structured framework of transition periods and time-limited derogations.

Scenario Question

We use PTFE tubing, FKM seals, PVDF filters, and fluoropolymer guidewire coatings in our devices. What does the EU PFAS restriction require of us and by when?

Direct Answer

The EU's broad REACH PFAS restriction is on track for adoption in 2027 following the European Chemicals Agency (ECHA) Committee for Risk Assessment (RAC) final opinion of March 2, 2026, and the Committee for Socio-Economic Analysis (SEAC) final opinion expected by the end of 2026. The regulation will ban PFAS after an 18-month transition period following its entry into force. However, specific medical device applications will benefit from time-limited derogations: either 18 months plus 5 years (a total of 6.5 years from entry into force) or 18 months plus 12 years (a total of 13.5 years from entry into force).

Medical devices are classified under Sector 9 (in-depth assessed) and Sector 19 (other medical applications). SEAC has concluded that most medical device derogations are justified or likely justified. Implantable medical devices and surgical meshes qualify for the maximum 13.5-year derogation. Manufacturers must inventory all PFAS-containing materials, map each component to its corresponding derogation tier, implement rigorous supplier traceability plans, and prepare for mandatory "Contains intentionally added PFAS" labeling and annual reporting requirements.

Which medical device components contain PFAS and fall in scope?

Under the proposed REACH restriction, PFAS is defined using the OECD (Organisation for Economic Co-operation and Development) grouping approach: any substance containing at least one fully fluorinated methyl ($-\text{CF}_3$) or methylene ($-\text{CF}_2-$) carbon atom (without any $\text{H}$, $\text{Cl}$, $\text{Br}$ or $\text{I}$ attached to it). This definition captures fluoropolymers, which are widely classified as "polymers of low concern" by industry groups but are legally included within the scope of this restriction due to persistence and emission concerns during their manufacturing and disposal lifecycles.

For device developers and quality engineers, identifying where PFAS resides within a product requires looking beyond obvious fluoropolymer parts. The table below outlines the primary PFAS-containing materials used in medical device components and their clinical functions:

Material Group	Common Material Names	Typical Medical Device Components	Critical Clinical Properties
Fluoropolymers	PTFE (Polytetrafluoroethylene), ePTFE (expanded PTFE)	Vascular grafts, surgical meshes, catheter shafts, guidewire liners, suture materials	Low coefficient of friction, high biocompatibility, non-thrombogenic surface
Fluorinated Elastomers	FKM (Fluorocarbon elastomer), FFKM (Perfluorocarbon elastomer)	O-rings, gaskets, seals, valve diaphragms in fluid pathways	Chemical resistance to aggressive drug formulations, high-temperature stability, low extractables
Thermoplastic Fluoropolymers	PVDF (Polyvinylidene fluoride), FEP (Fluorinated ethylene propylene), ETFE	Sterilization filters, dialysis membranes, heat-shrink tubing, wire insulation	Gamma-sterilization compatibility, high dielectric strength, precise pore-size control
Fluorinated Coatings	Perfluoroether-based coatings, fluorochemical surfactants	Guidewires, insertion cannulas, diagnostic microfluidic chips	Lubricious hydrophilic/hydrophobic coatings, precise fluid movement, anti-coagulation

The Supply Chain Challenge

The pervasiveness of these materials makes the EU PFAS restriction a major supply chain risk. Manufacturers often purchase sub-assemblies (such as coated needles, pre-assembled valves, or sterile packaging films) without knowing the exact chemical composition of each polymer or coating. A lack of transparency can lead to sudden supply disruptions if a sub-tier supplier decides to reformulate a component or discontinue a product line due to the regulatory burden in Europe.

For instance, PVDF is highly valued for diagnostic filtration membranes due to its chemical compatibility and structural integrity under pressure. If a filtration membrane manufacturer fails to secure or defend a derogation, a device maker could be forced to redesign their fluidics cartridge, triggering extensive design controls and regulatory submissions under the EU Medical Device Regulation (MDR 2017/745).

What are the timelines: 18-month transition, 5- and 12-year derogations, and the 13.5-year implant carve-out?

The REACH restriction timeline is structured around two key concepts: the general transition period and time-limited derogations.

Entry into Force (EIF): Anticipated in late 2027, following the adoption of the final restriction by the European Commission and its publication in the Official Journal of the European Union.
General Transition Period: 18 months from EIF (likely taking effect in mid-2029). After this date, all PFAS uses are banned unless a specific derogation applies.
Time-Limited Derogations: Formulated as 18 months plus an additional period of either 5 or 12 years. These derogations allow manufacturers to continue selling specific devices while developing and validating PFAS-free alternatives.

Derogation Tiers by Device Application

Under the ECHA RAC and SEAC recommendations, the medical device sector (Sector 9) is divided into specific derogation categories based on patient risk and substitution difficulty:

General Medical Devices (Non-Implantable): Transition period of 18 months plus 5 years (a total of 6.5 years from EIF). This applies to diagnostics, surgical instruments, and general hospital equipment using PFAS components where alternatives are actively being researched.
Active Implantable Medical Devices (AIMDs): Transition period of 18 months plus 12 years (a total of 13.5 years from EIF). This covers pacemakers, implantable cardioverter-defibrillators (ICDs), neurostimulators, and cochlear implants where materials like PTFE are essential for electrical insulation and long-term biocompatibility.
Implantable Medical Devices (Non-Active): Transition period of 18 months plus 12 years (a total of 13.5 years from EIF). This applies to orthopedic implants, heart valves, vascular grafts, stents, and surgical meshes.
In Vitro Diagnostics (IVDs): Transition period of 18 months plus 5 years (a total of 6.5 years from EIF). This covers microfluidic chips, reagent packaging, and analyzer components.

Interaction with National Bans

A major source of regulatory friction is the intersection of the upcoming EU-wide REACH restriction with national legislation.

Denmark: Executive Order BEK No. 464 (May 2, 2025) introduces a national ban on PFAS in consumer clothing, footwear, and waterproofing agents, enforced from July 1, 2026 (with a sell-through grace period until January 1, 2027). Importantly for device makers, the Danish ban exempts medical devices (alongside PPE and recycled goods) — it is a consumer-textile rule, not a device rule. Medical devices sold in Denmark remain governed by the forthcoming EU-wide REACH restriction rather than by this national order.
France: A national PFAS ban took effect on January 1, 2026, targeting cosmetics, textiles, and ski waxes, but currently excludes medical devices to prevent healthcare shortages.
Sweden (KEMI): The Swedish Chemicals Agency has been a primary driver of the dossier updates, advocating for strict substitution timelines while supporting long-term derogations for critical medical applications.

What concentration limits, labeling, and annual reporting duties apply to device makers?

The REACH PFAS restriction does not rely on a zero-tolerance standard; instead, it establishes three strict concentration thresholds. If a device component exceeds any of these thresholds, it is legally considered to contain PFAS and must comply with the restriction rules.

The Concentration Limit Trio

25 ppb (parts per billion) for any individual PFAS: Measured via targeted chemical analysis. This limit targets specific, high-concern small-molecule PFAS such as PFOA, PFOS, PFHxS, and PFNA.
250 ppb for the sum of targeted PFAS: The combined total of all individual PFAS substances identified during testing.
50 ppm (parts per million) for total fluorine: This threshold acts as a catch-all for polymeric PFAS (such as PTFE and PVDF) and fluorinated coatings. If total fluorine exceeds 50 ppm, the manufacturer must prove that the fluorine does not originate from PFAS substances; otherwise, the material is deemed restricted.

Mandatory Labeling and Disclosure

For any medical device or IVD placed on the EU market under a derogation, manufacturers must comply with new labeling requirements. The packaging and the instructions for use (IFU) must state clearly:

"Contains intentionally added PFASs"

This disclosure must be accompanied by the specific chemical name, the location of the PFAS within the device, and instructions for safe disposal to minimize environmental release. This requirement aligns with the broader EU goals under the Ecodesign for Sustainable Products Regulation (ESPR) and the upcoming EU Digital Product Passport (DPP), which mandates digital chemical-disclosure pathways.

Annual Reporting to ECHA

Manufacturers utilizing derogations are subject to annual reporting obligations under REACH. Every calendar year, the manufacturer must submit a dossier to ECHA containing:

The identity and quantity of PFAS-containing devices imported or sold in the EU.
The specific chemical names and CAS numbers of the PFAS substances used.
An updated justification detailing why PFAS remains technically necessary for the application.
A detailed progress report on substitution efforts, including testing results and timeline updates for transitioning to PFAS-free alternatives.

Which device uses did RAC and SEAC find justified, partly justified, or not assessed?

The European Chemicals Agency committees—the Committee for Risk Assessment (RAC) and the Committee for Socio-Economic Analysis (SEAC)—have conducted detailed assessments of medical device applications to determine which derogations are justified.

Implantable Devices and Surgical Meshes (Justified): SEAC concluded that the socio-economic benefits of maintaining access to ePTFE vascular grafts, hernia meshes, and heart valve components far outweigh the environmental risks. These applications receive the full 12-year derogation (13.5 years total).
Active Implantable Devices (Justified): AIMDs such as pacemakers and cochlear implants require high-reliability insulation and hermetic sealing. Alternatives do not currently exist with comparable long-term clinical data, justifying the 12-year derogation.
In Vitro Diagnostics (Justified): Calibration reagents and microfluidic channels requiring fluorochemical surfactants receive a 5-year derogation (6.5 years total) to allow for complete analytical re-validation.
Device Sterile Packaging (Partly Justified): Many sterile barrier systems rely on fluoropolymer coatings or additives to prevent puncture and ensure clean peeling. SEAC found this derogation partly justified, urging packaging suppliers to accelerate the adoption of alternative polymer blends.
Other Medical Applications (Sector 19 - Not In-depth Assessed): General laboratory equipment, specimen transport tubes, and non-critical laboratory consumables did not undergo in-depth assessment. These items generally face the standard 18-month transition unless manufacturers can submit strong site-specific socio-economic justifications.

RAC Emission Reduction Analysis

RAC's evaluation highlighted the environmental impact of these decisions. The committee compared two restriction options:

Restriction Option 1 (RO1 - Full Ban): A complete ban without derogations. RAC estimates this would cut PFAS emissions by 96% (avoiding approximately 3.3 million tons of PFAS emissions over a 30-year period). However, this would lead to widespread medical device shortages and severe patient harm.
Restriction Option 2 (RO2 - Ban with Derogations): The proposed approach featuring transition periods and derogations. This reduces emission-reduction effectiveness to 76% (permitting about 700,000 additional tons of PFAS emissions over 30 years). RAC accepted this compromise, stating that the health and safety of patients must take priority while substitution research continues.

Alternative Materials Analysis by Component Type

Developing a substitution roadmap requires a deep dive into material science. For each critical component, the replacement candidate must match or closely mimic the functional properties of the baseline PFAS material. The section below details the functional tradeoffs for the most common substitutions:

1. Sliding Surfaces and Liners (PTFE vs. UHMWPE)

PTFE is the gold standard for catheter liners, guidewire coatings, and syringe-plunger interfaces due to its exceptionally low static and dynamic coefficient of friction (typically 0.05 to 0.10).

Candidate Material: Ultra-High-Molecular-Weight Polyethylene (UHMWPE).
Technical Comparison: UHMWPE offers excellent wear resistance and a low coefficient of friction (0.10 to 0.15), making it a viable candidate for straight catheter shafts and guiding sleeves.
Functional Tradeoffs: UHMWPE has a lower melting point (135°C) compared to PTFE (327°C), which limits the thermal processing methods used during catheter reflow or extrusion. Additionally, UHMWPE is less flexible than PTFE, meaning that microcatheters utilizing UHMWPE liners may suffer from reduced trackability in tortuous vascular anatomy. Furthermore, UHMWPE does not accept hydrophilic coatings as easily as chemically etched PTFE, requiring secondary plasma treatment to ensure proper coating adhesion.

2. O-Rings and Fluidic Seals (FKM/FFKM vs. EPDM vs. Silicones)

FKM and FFKM elastomers are used in solenoid valves, chromatography fittings, and drug-delivery pumps where they provide excellent resistance to solvents, lipids, and aggressive pharmaceutical agents while maintaining seal integrity under high pressure.

Candidate Materials: Ethylene Propylene Diene Monomer (EPDM) and Liquid Silicone Rubber (LSR).
Technical Comparison: EPDM has excellent water and steam resistance, while LSR offers outstanding biocompatibility, flexibility, and a wide operating temperature range.
Functional Tradeoffs: EPDM exhibits poor resistance to oils, lipids, and hydrocarbon-based solvents, which can cause the seal to swell and fail in clinical applications involving lipid emulsions or organic drugs. LSR, while highly biocompatible, has high gas permeability and is susceptible to absorbing certain small-molecule drugs, potentially altering the delivered dose. Neither material can match the chemical inertness of FFKM, meaning that valve designs may need to incorporate physical isolation diaphragms to protect non-fluorinated seals from the drug path.

3. Filtration Membranes (PVDF vs. PES vs. Nylon)

PVDF is used in sterilizing-grade vent filters, IV line filters, and diagnostic sample-preparation cups because it can be cast into highly controlled pore sizes, exhibits low protein binding, and tolerates gamma irradiation, autoclave heat, and chemical sterilants.

Candidate Materials: Polyethersulfone (PES) and Nylon 6,6.
Technical Comparison: PES is highly hydrophilic and offers high flow rates, while Nylon is robust and naturally hydrophilic without surface modification.
Functional Tradeoffs: Nylon membranes are prone to swelling in aqueous environments and have higher protein binding, which can lead to target analyte loss in diagnostic assays. PES membranes, while excellent for aqueous filtration, have lower chemical resistance to alcohols and organic solvents compared to PVDF. Additionally, PES is more brittle, increasing the risk of membrane rupture during ultrasonic welding or cartridge assembly.

4. Lubricious Coatings (Fluoropolymer vs. Hyaluronic Acid / PEG)

Hydrophilic fluoropolymer coatings are applied to vascular guidewires and introduction sheaths to reduce insertion force and prevent tissue trauma.

Candidate Materials: Hyaluronic Acid (HA) hydrogels and Polyethylene Glycol (PEG) coatings.
Technical Comparison: Hydrogel coatings absorb water to create a highly slippery surface, achieving friction coefficients comparable to or lower than dry PTFE.
Functional Tradeoffs: Hydrogel coatings are susceptible to "particulate shedding"—the mechanical peeling of the hydrogel layer during passage through narrow or calcified vessels. These particulates can enter the bloodstream, posing micro-emboli risks. Fluoropolymer coatings, by contrast, are chemically bound and resist shedding. Transitioning to hydrogel coatings requires extensive particle characterization studies and clinical evaluation to satisfy regulatory concerns regarding embolic safety.

EU MDR / IVDR Regulatory Impact of Material Substitution

Replacing a PFAS material is not merely a manufacturing or engineering challenge; it is a major regulatory hurdle under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

1. Annex I General Safety and Performance Requirements (GSPRs)

Any material change directly impacts compliance with MDR Annex I Chapter II. GSPR 10 requires manufacturers to pay particular attention to:

The choice of materials used, particularly as regards toxicity and compatibility with inflammatory responses (GSPR 10.1).
The impact of processes on material properties, ensuring that design validation covers mechanical integrity and biocompatibility (GSPR 10.2).
Minimizing risks posed by substances that are carcinogenic, mutagenic, or toxic for reproduction (CMR), or endocrine-disrupting substances (GSPR 10.4).

Substituting PTFE or FKM requires re-running biocompatibility characterization in accordance with ISO 10993-1. This involves chemical characterization (ISO 10993-18), toxicological risk assessment (ISO 10993-17), and in vitro/in vivo testing (such as cytotoxicity, sensitization, irritation, and hemocompatibility for blood-contacting devices).

2. Significant Change Assessment (MDCG 2020-3)

Under the transition provisions of MDR Article 120 and the rules for CE-marked devices, any change in a device's design or intended purpose must be assessed to determine if it is a "significant change."

MDCG 2020-3 Guidance: A change in a raw material or component is considered significant if it affects the device's safety, performance, or clinical risk-benefit profile.
Regulatory Lead Times: If the material change is determined to be a significant change by the Notified Body, the manufacturer cannot implement it under a legacy MDD certificate or minor MDR change notification. The change requires a formal design dossier submission and prior approval from the Notified Body. In the current EU regulatory climate, Notified Body review queues for design variations range from 12 to 18 months, adding substantial lead time to any substitution project.

3. Clinical Evaluation Report (CER) Updates

Manufacturers must update the Clinical Evaluation Report (CER) to reflect the new material. If the manufacturer attempts to claim equivalence to their legacy PFAS-containing device, they must prove that the new material does not introduce new clinical risks or alter the device's thermodynamic, mechanical, or surface properties. If equivalence cannot be fully demonstrated through bench testing and literature reviews, the Notified Body may require clinical investigation data, such as a localized human clinical study, to verify safety and performance before approval.

How should manufacturers build a PFAS inventory, substitution roadmap, and supplier traceability plan?

To ensure compliance and maintain EU market access, medical device manufacturers must establish a structured, cross-functional PFAS compliance program. This program should connect regulatory affairs, quality systems, R&D, and procurement.

Step 1: Establish Supplier Traceability

Compliance begins with establishing material traceability. Quality managers should update their supplier quality management systems to require formal material disclosures from all raw material and component suppliers.

Material Disclosure Questionnaires: Require suppliers to provide Full Material Disclosures (FMDs) down to 100 ppm (0.01% by weight).
Certificates of Compliance (CoC): Obtain formal declarations stating whether any substance in the supplied part meets the OECD PFAS definition.
Testing Verification: For high-risk materials (such as imported polymers or unbranded coatings), perform independent laboratory testing for total fluorine (via Combustion Ion Chromatography) to verify supplier claims.

Step 2: Build a Comprehensive PFAS Inventory

Develop a centralized database containing all PFAS uses within the company's product portfolio. This inventory must record:

The part number and description of the PFAS-containing component.
The specific PFAS substance name and CAS number.
The total weight of the PFAS substance within the device.
The regulatory classification of the device (Class I, IIa, IIb, III under EU MDR).
The applicable derogation tier (5-year, 12-year, or none).
The annual sales volume of the device in the EU (to support ECHA reporting).

Step 3: Implement the Substitution Roadmap

For components qualifying for the 5-year or 12-year derogations, R&D teams must immediately establish a substitution project. Developing PFAS-free medical components is a multi-year process that requires:

Material Screening: Identify alternative polymers (e.g., UHMWPE, silicones) and assess suitability.
Bench Testing: Evaluate friction, wear, and mechanical properties.
Biocompatibility: Perform ISO 10993 testing (sensitization, cytotoxicity).
Design Controls: Execute design verification/validation (IQ/OQ/PQ) and record changes.
Regulatory Approval: Submit EU MDR variation notifications to Notified Bodies.

Identify Alternative Materials: For example, Ultra-High-Molecular-Weight Polyethylene (UHMWPE) can sometimes replace PTFE in low-friction sliding parts, while advanced silicones can replace FKM elastomers in certain sealing applications.
Perform Risk Management: Document the substitution risk profile in accordance with ISO 14971. A change in material can affect wear debris generation, biocompatibility, or sterilization compatibility.
Link to Quality Systems: The validation of new materials must run through formal design controls. This includes updating the device master record (DMR), revising the design history file (DHF), and executing process validation runs in line with statistical process control principles and packaging validation protocols under ISO 11607.

FAQs on EU PFAS Restrictions

Does the PFAS restriction apply to medical devices already regulated under MDR and IVDR?

Yes. The REACH PFAS restriction is a chemical-control regulation that applies horizontally across all industries. There is no exemption for medical devices or IVDs. Even if a device holds a valid CE Certificate under the EU MDR or IVDR, it must comply with REACH restriction requirements. Failure to meet the REACH concentration limits (or secure a valid derogation) will render the device illegal to sell in the EU.

What is the difference between RAC's full-ban recommendation and the derogation approach?

The Committee for Risk Assessment (RAC) evaluates the chemical risks and emission reduction potential. While RAC's technical preference is always a broad, rapid ban (RO1) to maximize environmental protection, they must weigh this against the socio-economic evaluations of the Committee for Socio-Economic Analysis (SEAC). SEAC evaluates the availability of alternatives and the health impact of shortages. The final restriction adopted by the European Commission represents a compromise (RO2) that implements a ban while granting long-term derogations for critical medical uses.

Will PTFE and ePTFE vascular grafts still be available in the EU?

Yes, for the medium term. ePTFE vascular grafts are classified as implantable medical devices. As such, they are eligible for the maximum 12-year derogation from the general transition date (totaling 13.5 years from entry into force). This timeline gives manufacturers until approximately 2041 to identify, validate, and secure regulatory approval for alternative biocompatible materials.

How do Denmark's and France's national PFAS bans interact with the EU restriction?

Under EU law, national bans can act as bridge regulations before an EU-wide REACH restriction is finalized. Denmark's consumer-textile ban, which takes effect on July 1, 2026, applies directly within Danish borders but exempts medical devices and PPE — so a device maker's Danish exposure runs through the EU-wide REACH restriction, not the Danish order. France's ban (effective January 1, 2026) targets cosmetics, textiles, and ski waxes and likewise does not reach medical devices. Once the EU-wide REACH restriction enters into force (anticipated late 2027), it will harmonize the PFAS rules across all 27 Member States, superseding conflicting national requirements.

Sources

European Chemicals Agency (ECHA): Registry of Restriction Intentions - PFAS Proposal. ECHA PFAS Restriction Update.
KEMI Swedish Chemicals Agency: Dossier on the universal restriction of PFAS under REACH (23 October 2025 revision). KEMI Official Portal.
PubMed (National Institutes of Health): Restriction of PFAS use in medical devices: challenges and roadmap for medical device manufacturers. PubMed ID 42429288.
EUR-Lex: Regulation (EU) 2025/40 on packaging and packaging waste, amending Regulation (EC) No 1907/2006 (REACH). EUR-Lex Portal.
MedTech Europe: Position paper on the universal REACH PFAS restriction proposal. MedTech Europe Resource Library.